TORONTO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed”, “DMED”, or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a leading provider of cutting-edge technology solutions for the hydrogen and life sciences industries, is pleased to announce significant progress in the commercialization of its proprietary electromagnetic heating technology for hydrogen production. Developed by Dr. Qingwang Yuan of the HOPE Group at Texas Tech University, this groundbreaking innovation enables the direct extraction of hydrogen from petroleum reservoirs and natural hydrogen fields, positioning DiagnaMed at the forefront of sustainable energy solutions.
Key Developments:
Advanced Technology Integration. DiagnaMed is integrating the newly licensed, state-of-the-art hydrogen generation technology from Texas Tech into its existing production systems. This enhancement is expected to drive increased efficiency, scalability, and cost-effectiveness in hydrogen production.
Strengthened Partnership with Québec Innovative Materials Corp. The long-standing alliance between DMED and QIMC is being bolstered through initiatives that leverage DMED’s enhanced hydrogen technology capabilities and QIMC’s industry-leading expertise in natural hydrogen. Together, the partners are positioned to expand renewable energy applications and accelerate the adoption of clean energy.
Commitment to Sustainability. DMED and QIMC remain dedicated to reducing greenhouse gas emissions and advancing the global shift to low-carbon energy. Their expanded collaboration reinforces a shared commitment to developing economically viable, environmentally responsible energy solutions.
Advancing Business Development and Partnering Discussions. DMED is committed to empowering the energy sector through repurposing existing oil and gas infrastructure, including over 25,000 active oil and gas fields and the 2-3 million abandoned wells in the United States, and accelerating the extraction of natural clean hydrogen from geologic hydrogen properties. DMED is in partnering discussions with petroleum and natural hydrogen exploration companies.
Fabio Chianelli, Chairman and CEO of DiagnaMed, commented:
“We are focused on commercializing our unique hydrogen production technology through strategic alliances with energy innovators, enabling cost-effective, carbon-neutral hydrogen production that aligns with global sustainability goals. We expect to engage with petroleum and natural hydrogen exploration companies that will further validate our business proposition and drive revenue at scale.”
About DiagnaMed
DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) delivers innovative technology solutions for the cleantech and life sciences industries, with a focus on hydrogen production and AI-driven drug discovery and diagnostics. Visit DiagnaMed.com.
For more information, please contact:
Fabio Chianelli
Chairman and CEO
DiagnaMed Holdings Corp.
Tel: 416-800-2684
Email: info@diagnamed.com
Website: www.diagnamed.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.
Cautionary Statement
Certain statements in this news release are forward-looking statements, including with respect to future plans, and other matters. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such information can generally be identified by the use of forwarding-looking wording such as “will”, “may”, “expect”, “could”, “can”, “estimate”, “anticipate”, “intend”, “believe”, “projected”, “aims”, and “continue” or the negative thereof or similar variations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including but not limited to, business, economic and capital market conditions, the ability to manage operating expenses, and dependence on key personnel. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future, anticipated costs, and the ability to achieve goals. Factors that could cause the actual results to differ materially from those in forward-looking statements include, the continued availability of capital and financing, litigation, failure of counterparties to perform their contractual obligations, loss of key employees and consultants, and general economic, market or business conditions. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in Company’s management’s discussion and analysis for the year ended September 30, 2024 (“MD&A”), dated January 28, 2025, which is available on the Company's profile at www.sedarplus.ca. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The reader is cautioned not to place undue reliance on any forward-looking information. The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
This news release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.
